date,title,source
Oct-19-18,MorphoSys's Licensee Janssen has Reported That New Tremfya(R) (Guselkumab) 3-Year Data Shows Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis,ACCESSWIRE
Nov-01-18,MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in Various Blood Cancer Indications at ASH 2018 Meeting,ACCESSWIRE
Nov-05-18,DGAP-News: MorphoSys AG Announces Third Quarter 2018 Results,ACCESSWIRE
Nov-15-18,"BRIEF-Morphosys, I-Mab Sign Agreement For Morphosys's Novel Immuno-Oncology Agent MOR210",Reuters
Nov-15-18,MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210,ACCESSWIRE
Nov-16-18,"The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal",Benzinga
Nov-19-18,MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa,ACCESSWIRE
Nov-20-18,"The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings",Benzinga
Nov-21-18,MorphoSys to Present at Upcoming Investor Conferences,ACCESSWIRE
Nov-26-18,MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis,ACCESSWIRE
Dec-07-18,"MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis",ACCESSWIRE
Dec-17-18,MorphoSys AG: Corporate Calendar 2019,ACCESSWIRE
Jan-17-19,MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis,ACCESSWIRE
Jan-18-19,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug",Benzinga
Jan-28-19,"European Shares Drop as Investors Await for Brexit, Fed, Trade",Bloomberg
Jan-31-19,MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab,ACCESSWIRE
Feb-19-19,"Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire",ACCESSWIRE
Feb-19-19,"Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire",ACCESSWIRE
Feb-21-19,MorphoSys to Present at Upcoming Investor Conference,ACCESSWIRE
Mar-04-19,"Invitation to Year-End Results 2018 Conference Call of MorphoSys AG on March 14, 2019",ACCESSWIRE
Mar-07-19,MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL,ACCESSWIRE
Mar-13-19,MorphoSys Presents Results for Fiscal Year 2018,ACCESSWIRE
